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ABSTRACT
Graft-versus-host disease (GVHD) is seen in skin, intestinal mucosa, and liver after autologous stem cell
transplantation. We reviewed 681 consecutive patients to estimate the probability of gastrointestinal (GI)
GVHD, response to treatment, risk factors for development, and effect on survival. GI GVHD was defined by
persistent symptoms, mucosal abnormalities at endoscopy, and histology showing apoptotic crypt cells with or
without lymphoid infiltrates. The proportion of patients with GI GVHD was 90/681 (13%). Nausea and
vomiting occurred in 90% and diarrhea in 40%. The mean time to developing symptoms was day 15, that to
histologically proven diagnosis was day 42, and that to starting prednisone treatment was day 45 after stem
cell infusion. Treatment with a short course of prednisone effected durable responses in 79% of patients, and
an additional 18% responded to a second course of prednisone. A multivariable logistic regression model
demonstrated that the combined factor of a diagnosis of breast cancer or hematologic malignancy and female
sex was statistically significantly associated with the probability of GI GVHD (P  .003). Survival in patients
with GI GVHDwas not statistically different than that in those without GVHD.We conclude that women with
breast cancer or hematologic malignancy are more likely to develop GI GVHD after autologous transplanta-
tion, and that treatment with prednisone was effective.
© 2006 American Society for Blood and Marrow Transplantation
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SNTRODUCTION
Acute graft-versus-host disease (GVHD) is a fre-
uent complication of allogeneic hematopoietic cell
ransplantation, characterized by skin, intestinal tract,
nd liver damage [1,2]. After syngeneic [3-5] or autol-
gous stem cell transplantation (ASCT), a GVHD-
ike syndrome, which is clinically and histologically
ndistinguishable from allogeneic GVHD, has been
escribed in the skin [3,6-11], intestinal tract [11,12],
nd liver [11,13]. The frequency of spontaneous skin
VHD after autologous transplantation is 5%-10%
8-10], but rates of 30%-80% have been reported after
nduction with cyclosporine-based therapy or inter- c
26eukin-2 (IL-2) [11,14,15]. The etiology of syngeneic
nd autologous GVHD is not well understood, but
here are 2 hypotheses, 1 related to dominance of
utoreactive T cells posttransplantation [15] and the
ther related to the presence of microchimeric (allo-
eneic) T cells [5].
The probability, risk factors, and morbidity of
pontaneously occurring gastrointestinal (GI) GVHD
n ASCT recipients remain poorly deﬁned. We pre-
iously reported a case series of 8 autograft recipients
ith histologically proven gastric GVHD and esti-
ated the frequency of this ﬁnding to be 4% [12].
ince ﬁrst recognizing this syndrome in 1995, we have
losely followed the course of 681 consecutive patients
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GI GVHD after Autologous Transplantation
Bho received autologous transplantation after myeloa-
lative therapy, 90 (13%) of whom developed biopsy-
roven GI GVHD. Here we report the course and
esponse to treatment for these patients, along with a
isk factor analysis for development of this syndrome.
ETHODS
atient Selection
We examined all patients who underwent myeloa-
lative ASCT at our center between July 1995 and
uly 1999 and evaluated those who experienced per-
istent GI symptoms, as described later. Review of
atient records was carried out under the aegis of a
rotocol approved by our Institutional Review Board.
n this series, no patient received stem cells from a
yngeneic donor.
utologous Transplantation Technique
The majority of patients were conditioned for
ransplantation with busulfan/melphalan/thioTEPA
BUMELT) [16], total body irradiation/cyclophospha-
ide/etoposide [17], busulfan/cyclophosphamide, cyclo-
hosphamide/total body irradiation, busulfan/cyclo-
hosphamide/total body irradiation, I131-radiolabeled
ntibody to CD20 with or without cyclophosphamide/
otal body irradiation [18], melphalan/thioTEPA, busul-
an, or BCNU/etoposide/araC/melphalan (BEAM).
nce at our center, all patients received irradiated
lood products. Unfortunately, transfusion history
utside of our center could not be accurately deter-
ined from the medical records provided to us. Flu-
onazole was given from conditioning therapy until
ay 75 after stem cell infusion. All patients received
rophylactic antibiotics when the absolute neutrophil
ount (ANC) reached 5.0  109/L. Patients who
ere serologically positive for herpes simplex virus
HSV) received prophylactic low-dose acyclovir until
ngraftment. Patients had weekly cytomegalovirus
CMV) screening with a CMV pp65 antigenemia as-
ay (CMV Brite; Biotest Diagnostics, Denville, NJ)
nd viral blood testing from day 10 through day
100 after stem cell infusion or until discharge from
ur system, as described previously [19]. Patients with
positive quantitative CMV antigenemia test (5
ells/slide) received antiviral therapy with ganciclovir.
valuation of GI Symptoms
Patients were evaluated for development of symp-
oms of nausea, vomiting, anorexia, dysphagia, heart-
urn, abdominal pain, and diarrhea up to 100 days
ost–stem cell infusion. The Gastroenterology/Hepa-
ology Service evaluated patients who exhibited the
ersistence of 1 or more of these symptoms beyond
ay 15 post–stem cell infusion. Evaluation consisted
f history, physical examination, laboratory tests (se- a
B&MTum liver tests, lipase, stool cultures, and microscopy),
nd an imaging study (computed tomography, x-ray,
r ultrasonography) if clinically indicated [12,20]. GI
ymptoms, such as nausea/vomiting, anorexia, and di-
rrhea, were graded from 0 (no symptoms) to 3 (se-
ere) [21,22]. When a clear etiology for these symp-
oms could not be identiﬁed, upper GI endoscopy or
olonoscopy and mucosal biopsy were performed under
onscious sedation using video endoscopy and sterile
iopsy forceps for mucosal biopsy, as described previ-
usly [22,23]. Endoscopic ﬁndings were graded as 0,
o abnormality; 1, mild mucosal edema/erythema; 2,
oderate mucosal edema/erythema; 3, severe mucosal
dema/erythema; 4, focal mucosal ulceration; or 5,
iffuse mucosal ulceration. Biopsy specimens taken
rom 4 sites in the gastric antrum and from any other
bnormal-appearing mucosa were placed in B5 forma-
in for histology (hematoxylin & eosin, methenamine
ilver, and Brown-Hopps tissue Gram stain), in rapid
rease test kits for detection of Helicobacter pylori
CLO test; DeltaWest, Bentley, Australia), and in veal
nfusion broth for viral culture and tested for fungal
athogens. Viral culture methods included both con-
entional ﬁbroblast cell culture for microscopic exam-
nation of cytopathic alterations and centrifugation
ell culture for rapid diagnosis of CMV by indirect
mmunoﬂuorescence [24].
iagnosis of Autologous GI GVHD
A diagnosis of GI GVHD was made if the follow-
ng criteria were met: (1) ongoing GI symptoms, (2)
ndoscopy or colonoscopy showing abnormal mucosa
n the stomach, duodenum, or colon [25]; (3) histo-
ogical ﬁndings in the biopsy specimens showing ap-
ptotic crypt epithelial cells with or without lympho-
ytic aggregates, or crypt cell dropout with focal
ymphocytic inﬁltration [25-27]; and (3) negative re-
ults for viral, bacterial, and fungal pathogens from
ultures of stool, mucosal brushings, and biopsy tissue
rom mucosa involved with GVHD [23,24].
esponse of GI Symptoms to Treatment
We deﬁned a durable response to treatment as the
isappearance of the presenting signs and symptoms
f autologous GVHD of the stomach or intestines
uring the treatment period and the absence of recur-
ent symptoms after treatment was discontinued. Re-
eat endoscopy was not carried out in patients whose
ymptoms ceased. A partial response was deﬁned as a
ecrease in GI signs and symptoms during the treat-
ent period but the return of these symptoms after
iscontinuation of treatment. No response was deﬁned
s the persistence of symptoms despite treatment.
227
Ss
a
p
(
o
n
m
a
c
c
v
a
i
w
n
m
o
m
C
g
u
m
R
P
b
b
w
n
2
o
m
m
r
c
d
C
a
I
S
d
p
d
d
p
G
p
S
c
t
o
w
i
n
p
w
a
O
h
n
G
b
c
T
G
A
S
P
P
B
B
P
C
I
L. Holmberg et al.
2tatistical Methods
The probability of GI GVHD was estimated using
imple proportions. Logistic regression was used to
ssess the association of potential risk factors with this
robability. Factors examined included sex, diagnosis
breast cancer vs lymphoma, multiple myeloma [MM],
r a hematologic malignancy [HM] vs other diag-
oses), use of IL-2 therapy, source of stem cells (bone
arrow [BM] vs peripheral blood stem cells [PBSCs]),
ge at transplantation, use of CD34-selected stem
ells, conditioning regimen (BUMELT vs radiation-
ontaining vs other), parity (among females), and gra-
idity (among females). The factors sex and diagnosis
re highly correlated and thus were combined, result-
ng in the following categories: breast cancer; male
ith lymphoma, MM, or HM; male with other diag-
osis; female with lymphoma, MM, or HM; and fe-
ale with other diagnosis. The impact of GI GVHD
n the risk of relapse and mortality was assessed by
odeling GVHD as a time-dependent covariate in a
ox regression model. Two-sided P values from re-
ression models were derived from the Wald test
nless otherwise speciﬁed, and no adjustments were
ade for multiple comparisons.
ESULTS
atient Characteristics
Most patients were adults, with 54% women (Ta-
le 1). Information about previous pregnancies and
irths was available from 330/367 women, most of
hom had been pregnant (264/330; 80%). The diag-
oses leading to transplantation were lymphoma (n 
57), breast cancer (n  179), myeloma (n  83),
ther hematologic malignancies (n  40), other tu-
able 1. Characteristics of 681 Consecutive Recipients of Autologous Ste
astrointestinal Tract
ge (mean  SD, years)
ex (F/M)
regnancies (female patients)
Nulligravid
Gravid
(Single/multiple births)
Pregnancy history unknown
arity (female patients)
Nulliparous
Parous
(Single/multiple births)
Parity history unknown
reast cancer/hematologic malignancies/other diagnoses
usulfan/melphalan/thioTEPA versus other conditioning regimen
eripheral blood stem cells/bone marrow
D34 selected stem cells
L-2 therapy posttransplantationors (n  106), and other conditions (n  16). The w
28ost common conditioning regimen was BUMELT,
eceived by 389/681 patients (57%). Most patients re-
eived autologous PBSCs (650/681; 95%); the remain-
er received BM. Sixty-four patients (9%) received
D34-selected stem cells, and 87 (13%) received IL-2
fter transplantation.
ncidence of Autologous GVHD Involving the
tomach and Intestinal Tract
Of 681 patients who underwent transplantation
uring the 4-year period, 109 patients (16%) had
ersistent GI symptoms after transplantation and un-
erwent intestinal endoscopy with mucosal biopsy. A
iagnosis of biopsy-proven GVHD was made in 90
atients (13%). Of note, skin lesions consistent with
VHD were present in only 9 patients (1%), and no
atient in this series had evidence of hepatic GVHD.
ymptoms of GI GVHD
Persistent nausea and vomiting were the most
ommon symptoms of GVHD, affecting 81/90 pa-
ients (90%) (Table 2). Two patients presented with
nly anorexia, 3 patients with only diarrhea, 3 patients
ith only dysphagia, and 1 patient with only abdom-
nal pain. In 41 of the 81 patients, anorexia accompa-
ied nausea and vomiting, and in 33, diarrhea was also
resent. The severity of nausea, vomiting, or anorexia
as generally moderate, but some patients were dis-
bled by incessant vomiting and profound anorexia.
nly 40% of all patients with a diagnosis of GVHD
ad diarrhea, which was generally mild. There were
o cases of severe diarrhea. The mean time to onset of
I symptoms was day 15 post–stem cell infusion,
ut some patients developed symptoms within days of
ompleting conditioning therapy that did not resolve
s, by the Presence or Absence of Autologous GVHD Involving the
No Autologous GVHD
(n  591)
Autologous GVHD Present
(n  90)
44  15 44  14
301/290 (51%/49%) 66/24 (73%/27%)
53 (18%) 13 (20%)
215 (71%) 49 (74%)
(47/168) (13/36)
33 4
69 (23%) 20 (30%)
210 (70%) 44 (67%)
(35/175) (9/35)
22 2
140/345/106 (24%/58%/18%) 39/35/16 (43%/39%/18%)
324/267 (55%/45%) 65/25 (73%/27%)
560/31 (95%/5%) 90/0 (100%/0%)
54 (9%) 10 (11%)
69 (12%) 18 (20%)m Cell
sith the passage of time. However, most patients
e
l
v
a
E
d

8
B
w
a
f
w
i
8
i
a
m
m
t
s
i
O
t
H
c
i
(
a
6
2
d
a
R
s
s
a
s
n
p
l
d
d
m
p
(
s
u
t
r
r
n
3
f
t
p
3
c
f
p
t
i
O
r
n
l
i
a
1
t
w
T
(
h
o
u
m
t
s
t
i
T
N
A
D
GI GVHD after Autologous Transplantation
Bxperienced resolution of conditioning therapy–re-
ated symptoms but later developed anorexia, nausea,
omiting, or diarrhea, with onset of symptoms as late
s day 77 post–stem cell infusion.
ndoscopic Findings
The mean time to ﬁrst diagnostic endoscopy was
ay 42  17 after stem cell infusion (range, day
18-day 98), with upper endoscopy performed in
7 patients and colonoscopy performed in 3 patients.
ecause the mean time to endoscopy or colonoscopy
as 42 days after stem cell infusion, we believe that
dequate time was allowed for the patients to recover
rom acute conditioning toxicity before the procedure
as done to assess for GVHD. Endoscopic abnormal-
ties were found more often in the stomach, where
2/87 patients (94%) had mucosal abnormalities, than
n the duodenum, where 47/86 patients (55%) had
bnormal-appearing mucosa. Colonic mucosal abnor-
alities were seen in 2 of 3 patients. Most of the
ucosal abnormalities consisted of grades 1–2 (mild
o moderate) mucosal edema and erythema; however,
ome patients had severe grade 3 edema and erythema
n the gastric (n  12) or duodenal mucosa (n  5).
ne patient had grade 4 focal mucosal ulceration in
he stomach.
istological Findings
The most common histological ﬁnding in the mu-
osal biopsy specimens was apoptosis of epithelial cells
n gastric or colonic crypts, found in 82/90 patients
91%). Crypt cell apoptosis was frequently found in
ssociation with focal lymphoid aggregates (61/90;
8%), but was also seen as an isolated ﬁnding (21/90;
3%). Eight patients (9%) exhibited histological evi-
ence of crypt cell dropout and focal lymphocyte
ggregates.
esponse to Treatment
A total of 82 patients were treated with cortico-
teroids (70 with prednisone; 9 with oral beclometha-
one dipropionate at 8 mg, given in 4 divided doses in
n emulsion formulation; and 3 with oral beclometha-
one dipropionate for a few days followed by pred-
able 2. Onset and Severity of the Symptoms of Gastrointestinal GVH
Number of
Patients
ausea/vomiting with or without
anorexia or diarrhea 81
norexia with or without
nausea/vomiting or diarrhea 43
iarrhea with or without
anorexia or nausea/vomiting 36isone). The initial dose of oral prednisone in 67/73 c
B&MTatients (92%) was 1 mg/kg/day for 10-4 days, fol-
owed by a slow tapering of the dose. A prednisone
ose of 0.5 mg/kg/day was given to 1 patient, and a
ose of 2 mg/kg/day was given to 5 patients. The
ean day for initiation of treatment was day45 19
ost–stem cell infusion (range, day 22-day 103).
Durable Responses. Sixty-ﬁve of 82 treated patients
79%) had a cessation of all GI symptoms that was
ustained after corticosteroid therapy was discontin-
ed. There was only a short interval from the start of
herapy to improvement in symptoms (median, 4 days;
ange, 1-12 days). Of the 65 patients with a durable
esponse to therapy, 56 had been treated with pred-
isone, 6 with oral beclomethasone dipropionate, and
with a few days of oral beclomethasone dipropionate
ollowed by prednisone. The mean full duration of
herapy, including time to complete a tapering of the
rednisone dose to avoid adrenal insufﬁciency, was
9  17 days (range, 3-95 days). There were no major
omplications of corticosteroid therapy, although in-
ection at baseline in 2 patients led to management
roblems. One patient developed oral HSV infection;
reatment with acyclovir was started 5 days before the
nitiation of a 2-week course of prednisone therapy.
ne patient developed parainﬂuenza pneumonia and
espiratory insufﬁciency 5 days before starting pred-
isone therapy and died of respiratory failure 2 weeks
ater.
Partial Responses. Seventeen patients experienced
mprovement in symptoms in response to initial ther-
py (12 treated with prednisone 1 mg/kg/day for
0-14 days, followed by a tapering of the dose; 2
reated with prednisone 2 mg/kg/day; and 3 treated
ith oral beclomethasone dipropionate emulsion).
he median duration of initial therapy was 31 days
range, 10-51 days). But all patients in this latter co-
ort experienced recurrent nausea, vomiting, or an-
rexia after corticosteroid treatment was discontin-
ed. All patients underwent repeat endoscopy, at a
edian of 19 days from the ﬁnal day of corticosteroid
reatment (range, 4-49 days). Gastric mucosal biopsy
pecimens exhibited epithelial cell apoptoses in 14 of
he 17 patients, with focal lymphoid aggregates found
n the remaining 3 patients. Retreatment with corti-
Patients
n Day Post–Stem Cell Infusion
to Onset of Symptoms
Severity of Symptoms
(Range, 0-3)
14.9  18.4 (range, 0-77) 1.6  0.6 (range, 1-3)
14.3  19.3 (range, 0-77) 1.8  0.6 (range, 1-3)
14.5  16.1 (range, 0-63) 1.5  0.5 (range, 1-2)D in 90
Meaosteroids was initiated in the former group of 14
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2atients (prednisone starting doses of 1 mg/kg/day in
2, 1.5 mg/kg/day in 1, and 2 mg/kg/day in 1). The
edian time to improvement in symptoms was 4 days
range, 2-14 days). All 14 patients had durable re-
ponses to this second course of corticosteroid ther-
py. After a median treatment period of 34 days
range, 15-64 days), there were no recurrences of
ymptoms after discontinuation of prednisone. One
atient had treatment deferred because of reactivation
f hepatitis B virus, but after a third endoscopy
howed autologous GVHD, this patient was treated
ith prednisone, 1 mg/kg/day, and achieved a durable
esponse. Two patients whose recurrent symptoms
ere mild were never retreated.
Untreated Patients. Eight patients received no
reatment despite gastric mucosal abnormalities on
ndoscopy and abnormal histology consistent with
utologous GVHD. Three patients presented with
ysphagia as their only GI symptom; 2 of these pa-
ients improved after treatment for reﬂux esophagitis,
nd 1 improved after ganciclovir therapy was begun
or CMV esophagitis. One nauseated patient had
sophageal CMV and gastric GVHD diagnosed at
ndoscopy and improved after ganciclovir therapy.
hree patients with mild symptoms improved without
herapy. One patient with persistent, moderately se-
able 3. Univariate Logistic Regression Models for Development of
utologous GVHD
OR 95% CI P Value
ge (years)* 1.03 0.89-1.21 .70
ex
Male 1 — —
Female 2.65 1.62-4.34 .0001
arity (females only)
Nulliparous 1 — —
Parous 0.72 0.40-1.31 .28
regnancy (females only)
Nulligravid 1 — —
Gravid 0.93 0.47-1.84 .83
iagnosis
Other diagnoses 1 — —
Breast cancer 1.85 0.98-3.48 .06
Hematologic malignancy 0.67 0.36-1.26 .22
tem cell source
Bone marrow 1 — —
Peripheral blood  — .003†
onditioning regimen
BUMELTT 1 — —
Other 2.28 1.39-3.74 .001
D 34 selection of infused
stem cells
Unselected 1 — —
Selected 0.79 0.39-1.58 .50
nterleukin-2 therapy
No 1 — —
Yes 1.89 1.07-3.36 .03
Modeled as a continuous linear variable, with odds ratio presented
as increase in odds for each 10-year increase in age.
P value obtained from likelihood ratio test.ere nausea, vomiting, anorexia, and diarrhea under- *
30ent endoscopy 3 times over 79 days of observation,
nd each endoscopy showed GVHD, which was never
reated.
nalysis of Risk Factors for the Development
f Autologous GI GVHD
In a univariate analysis, potential risk factors, in-
luding age, sex, pregnancy history, disease type, stem
ell source, transplantation conditioning regimen,
BSC graft manipulation with or without CD34 se-
ection, and addition of immunotherapy, were as-
essed. The ﬁndings are summarized in Table 3.
All patients diagnosed with breast cancer were
emale, so the impact of sex was examined in the
atients with diagnoses other than breast cancer. The
mpact of sex appeared to differ in those patients with
hematologic malignancy compared with those with
ther diagnoses (excluding breast cancer) (P .04), so
ex and diagnosis were combined into a single variable
ith categories as described earlier in Statistical
ethods. Table 4 summarizes results from a multiva-
iable logistic regression model, including the use of
his combined factor.
The odds of GI GVHD were 3.27 times higher in
emales with breast cancer compared to males with a
ematologic malignancy (95% conﬁdence interval 
.72-6.22; P  .0003). Women with a diagnosis of
ematologic malignancy also had a higher risk than
en with a hematologic malignancy (odds ratio
OR]  2.95; 95% conﬁdence interval [CI]  1.44-
.01; P .003), suggesting a sex effect in patients with
uch a diagnosis. Such an effect does not appear to
xist among patients with other diagnoses, however;
he risk of GI GVHD is actually lower in females than
n males in this group. The use of BUMELT is sug-
estively associated with an increased probability of
able 4. A Multivariable Logistic Regression Model for Development
f Gastrointestinal Autologous GVHD
Factor OR 95% CI P Value
ex/Diagnosis
Male/hematologic
malignancy 1 — —
Female/breast cancer 3.27 1.72-6.22 .0003
Female/hematologic
malignancy 2.95 1.44-6.01 .003
Male/other diagnoses 2.82 1.13-7.09 .03
Female/other
diagnoses 2.12 0.86-5.24 .10
nterleukin-2 therapy
No 1 — —
Yes 1.79 0.98-3.26 .06
onditioning regimen
BUMELTT 1 — —
Other 1.69 0.98-2.89 .06
tem cell source
Bone marrow 1 — —
Peripheral blood  — .02*P value obtained from likelihood ratio test.
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GI GVHD after Autologous Transplantation
Butologous GI GVHD compared with all other regi-
ens, and although the majority (87%) of patients
ith breast cancer received BUMELT, the impact of
UMELT was roughly the same across the 3 disease
ategories (P  .34 for breast cancer vs hematologic
alignancy; P  .76 for hematologic malignancy vs
ther diagnoses). The use of PBSC and IL-2 therapy
ere also associated with suggestively increased risk of
I GVHD compared with the use of BM and no
mmunotherapy, respectively. Among female patients,
arous women were less likely to develop GI GVHD
han nulliparous women after adjusting for the rele-
ant factors listed in Table 4, but the difference was
ot statistically signiﬁcant (OR  0.60; P  .13; like-
ihood ratio test).
ffect of Autologous GI GVHD on Mortality
The hazard of mortality in patients with autolo-
ous GI GVHD was lower than that in patients with-
ut GVHD, but the difference was not statistically
igniﬁcant (hazard ratio  0.89; 95% CI  0.64-1.22;
 .46). The magnitude of association between
VHD and the hazard of mortality was not sugges-
ively different across disease groups (data not shown).
ISCUSSION
The major ﬁndings of this study can be summa-
ized as follows:
. Autologous GVHD involving the GI tract developed in
13% of the patients and was responsive to a single course
of prednisone therapy in most of these patients.
. Both female sex and diagnosis are associated with the
development of autologous GI GVHD, with the impact
of sex apparently depending on diagnosis.
The clinical presentation of autologous GI GVHD
as identical to that of recipients of allogeneic hema-
opoietic stem cells who develop nausea, vomiting,
nd anorexia [21,22,27,28]. Diarrhea, usually mild to
oderate in severity and almost always associated with
ausea or anorexia, occurred in 40% of the patients.
he endoscopic appearance and histology of the mu-
osa in the stomach and duodenum were identical to
hose of allogeneic GVHD. (Color plates of endo-
copic photographs [25] and gastric mucosal histology
12] have been published previously.) A short treat-
ent course of prednisone resulted in complete, du-
able resolution of symptoms in 79% of the treated
atients. An additional 18% of patients were retreated
nd had complete, durable responses to another
ourse of corticosteroid therapy. In our previous re-
ort of patients undergoing autologous hematopoietic
ell transplantation, we made a diagnosis of autolo-
ous GI GVHD in 4% of cases [12]. The 13% inci-
ence in the current series reﬂects an increased aware-
ess of this syndrome among our clinical staff, along t
B&MTith an imperative to discover a cause for persistent
I symptoms before patients were returned to the
are of their referring physicians. Our current practice
s to consider the diagnosis of autologous GI GVHD
n patients whose appetite is not improving by day
15-20 after stem cell infusion, and to perform en-
oscopy in all patients whose intestinal symptoms per-
ist beyond day 25 to evaluate for GVHD, enteric
nfection by bacteria and viruses (especially CMV), or
ersistence of signiﬁcant conditioning-related entero-
olitis [23,24,29].
In our study, all patients who developed autolo-
ous GVHD received granulocyte colony-stimulating
actor (G-CSF)-mobilized PBSC grafts. These grafts
re known to have 10 times more T cells and 50 times
ore monocytes than BM [30]. Conditioning with
UMELT was also suggestively associated with au-
ologous GI GVHD (adjusted OR  1.69; P  .06),
nd this effect did not appear to be due solely to its use
mong patients with breast cancer. This regimen is
nown to cause signiﬁcant GI toxicity [16,31-33]. In
ur study of syngeneic graft recipients, we also ob-
erved an association between GVHD and BUMELT
onditioning therapy (P  .01) [5]. We speculate that
I mucosal damage from this preparative regimen
ncreases the risk of autologous GI GVHD. Activated
ytotoxic T cells cause further damage directly to the
I mucosa. Because early after transplantation, thy-
ic function is poor and older patients are not likely
o have much thymus function even before transplan-
ation, thymic dysfunction makes our patients more
usceptible to developing autoreactive immune cells.
n addition, immune regulatory cells that control the
ctivity of autoreactive cells are decreased in the pe-
iphery by the conditioning transplantation regimen.
his decrease in immune regulatory cells and subse-
uent decrease in immune regulatory cytokines, such
s transforming growth factor -1, may increase the
bility to develop autoreactive cells. Thus, all of these
hanges contribute to tipping the balance toward be-
ng able to generate autologous GVHD.
In patients with hematologic malignancies or
reast cancer, a graft-versus-tumor effect with de-
reased relapse rates and survival beneﬁt has been
eported for patients who develop cyclosporine-in-
uced autologous GVHD [34-40]. Both animal mod-
ls and clinical trials suggest that the use of cyclospor-
ne results in a permissive environment that maximizes
arly after autologous transplantation the development
f autoreactive cells. Autologous GVHD results not only
rom the failure to inhibit the deletion of autoreactive
cells by the thymus, but also from the elimination of
eripheral immunoregulatory cells [15]. We could not
emonstrate a survival beneﬁt from the mainly sponta-
eous GI GVHD in our patient cohort as a whole or in
ny single disease cohort. However, controversy exists as
o which types of immune cells are most important for
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2graft-versus-tumor effect. In cyclosporine-induced
odels of GVHD, perforin/grazyme B-containing
ells are preferentially increased over FAS/FAS ligan-
–containing cells, which are increased only margin-
lly [41]. In allogeneic GVHD disease, initially FAS/
AS ligand–-containing cells were felt to be more
mportant in tumor control [42]. Other studies indi-
ate that perforin pathways are more important than
AS/FAS ligand pathways in differentiating the cells
hat cause allogeneic GVHD from those that have a
raft-versus-tumor effect [43]. Because we do not
now which types of immune cells are associated with
he mainly spontaneous, non–cyclosporine-induced
utologous GI GVHD reported here, it is possible
hat the cells mediating predominately autologous GI
VHD are not those that contribute to a graft-versus-
umor effect.
An interesting ﬁnding in this series is the differ-
ntial association of autologous GI GVHD with fe-
ale sex according to diagnosis. Females with breast
ancer were more likely to develop GI GVHD com-
ared with males with hematologic malignancy, but it
s not possible to ascribe this association to sex or
iagnosis. A sex effect was seen in patients with a
ematologic malignancy, however, where females had
early 3 times the odds of GVHD compared to males.
uch an effect was not seen in patients with other
iagnoses, however. Females with breast cancer and
hose with a hematologic malignancy had an increased
isk of GI GVHD compared with females with other
iagnoses, but neither association was statistically sig-
iﬁcant (OR  1.54, P  .32 for breast cancer; OR 
.39, P  .47 for hematologic malignancy) One hy-
othesis to explain the association of female sex with
VHD is a biologically plausible one: Pretransplan-
ation hematopoietic microchimerism results in the
ransplantation of both autologous and allogeneic im-
une cells, and these allogeneic cells lead to GVHD.
icrochimerism can be established in 2 ways. First,
omen have a higher frequency of microchimerism
han men, as a result of fetal cells in the maternal
irculation during and for decades after pregnancy
44]. Recently, male DNA has been frequently found
n the G-CSF–mobilized apheresis PBSC product
rom normal female donors [44,45]. Donor parity is
eportedly associated with syngeneic and allogeneic
VHD, thought to be related to allosensitization of
aternal T cells to fetal antigens during pregnancy,
hus priming these cells to recognize similar antigens
n recipients of hematopietic cells from parous donors
46-48]. Our group has recently reported that synge-
eic GVHD occurs more frequently when the donor
s a parous female (32%) rather than a nulliparous
emale (9%) or a male (13%) (P  .03). In addition,
yngeneic GVHD is associated with the parity of the
yngeneic recipient; a parous female (31%) is more
ikely to develop GVHD than a nulliparous female
327%) or a male (13%) (P  .02) [5]. In the current
nalysis, we were not able to show a statistically sig-
iﬁcant association between parity or gravidity of our
emale patients and the risk of developing autologous
I GVHD.
The second mechanism for microchimerism is
hrough blood transfusions. However, we were unable
o provide data on this alternate mechanism by which
ur patients may have become microchimeric, that is,
hrough transfer of allogeneic cells through transfu-
ion of unirrradiated blood products. Before receiving
yeloablative autologous transplantation, a patient
ften undergos many courses of therapy, and may not
ave been immunologically competent enough to re-
ect allogeneic cells transfused in unirrradiated blood
roducts. Microchimerism acquired through blood
roduct transfusion applies equally to all patients in
ur study cohort, including both men and nulliparous
omen. We could not test this hypothesis, because we
acked detailed history of blood transfusions before
he patients entered our system and did not test pa-
ients’ blood or stem cell products using molecular
ethods to detect microchimerism.
If the microchimerism hypothesis of GVHD in
utologous graft recipients is correct, then this disorder
hould be more properly called allogeneic GVHD. Un-
ike the situation in allogeneic hematopoietic cell
ransplantation, most of our patients responded to a
hort course of corticosteroid therapy, suggesting that
LA-disparate cells or autoreactive cells were easily
ejected or destroyed.
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